Croda wraps up Solus Biotech acquisition

By Julia Wray | Published: 5-Jul-2023

Chemicals giant plans to establish biotech R&D hub in Korea on back of deal

British specialty chemicals manufacturer Croda has completed its acquisition of Solus Biotech.

Croda first made public its intention to buy the Korean company, which specialises in biotechnology-derived beauty actives, in February.

The chemicals giant said it intends to expand its Asian manufacturing capabilities on the back of the deal.

It plans to create a new biotech R&D hub in the region to work in synergy with Croda’s R&D centre in LePerray, France – part of its Sederma business.

Additionally, Solus’ phospholipids will be incorporated into Croda’s skin care and hair care franchises.

“This is a very exciting opportunity for Croda,” said Luc Emprin, Global Business Director of Sederma.  

“Our existing ceramides, currently from Sederma, will be complemented by these natural fermentation-derived ceramides, furthering our portfolio of high efficacy science-based ingredients.

“We are pleased to add Solus' manufacturing site in South Korea to our operations, furthering our growth strategy for this key region.

“Innovation synergies between our different R&D labs will bring additional technical value and business opportunities for our customers all over the world.”

Read more:

Relevant companies

You may also like